Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner, +27

JAMA

Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China

Penghui Shang, Yinyin Xia, Feiying Liu, +28

PLoS ONE

Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial

Linong Ji, Xiaolin Tong, Hongyuan Wang, +18

PLoS ONE

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Young‐Suk Lim, Henry Lik‐Yuen Chan, Kosh Agarwal, +19

Alimentary Pharmacology & Therapeutics

[Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction].

Shen-yan Wang, Xue-lihong Wang, Hong Zeng, +6

PubMed

Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes

Yingying Luo, Sanjoy K. Paul, Xianghai Zhou, +6

Journal of Diabetes Research

The Seasonality of Acute Attack of Primary Angle-Closure Glaucoma in Beijing, China

Jingyuan Zhu, Yang Xu, Hongyuan Wang, +3

Scientific Reports

A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes

Yingying Luo, Hongyuan Wang, Xianghai Zhou, +6

Journal of Diabetes Research

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Scott Fung, Calvin Q. Pan, Grace Lai–Hung Wong, +16

Alimentary Pharmacology & Therapeutics